HSBC/CALL/EVOTEC/40/0.1/19.06.24 Share Price

Warrant

DE000TT73W77

Market Closed - BOERSE MUENCHEN 01:07:00 28/05/2024 am IST
0.001 EUR 0.00% Intraday chart for HSBC/CALL/EVOTEC/40/0.1/19.06.24
1 month-90.91%
3 months-90.91%
Date Price Change
27/24/27 0.001 0.00%
24/24/24 0.001 0.00%
23/24/23 0.001 0.00%
22/24/22 0.001 0.00%
21/24/21 0.001 0.00%

Real-time BOERSE MUENCHEN

Last update May 28, 2024 at 01:07 am IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer HSBC
WKN TT73W7
ISINDE000TT73W77
Date issued 13/07/2021
Strike 40
Maturity 19/06/2024 (23 Days)
Parity 10 : 1
Emission price 0.84
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.37
Lowest since issue 0.001
Spread 0.032
Spread %96.97%

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.18 EUR
Average target price
20.79 EUR
Spread / Average Target
+126.47%
Consensus